Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 27:14:3027-3034.
doi: 10.2147/JMDH.S337258. eCollection 2021.

COVID-19 Screening for Hospitalized Patients: The Role of Expanded Hospital Surveillance in a Low Prevalence Setting

Jen-Yu Hsu  1 , Po-Yu Liu  1 , Chien-Hao Tseng  1 , Chia-Wei Liu  1 , Wan-Ting Yang  1 , Wei-Hsuan Huang  1 , Shu-Yuan Li  1 , Ya-Chun Liao  1 , Ming-Ju Wu  2
Affiliations

COVID-19 Screening for Hospitalized Patients: The Role of Expanded Hospital Surveillance in a Low Prevalence Setting

Jen-Yu Hsu et al. J Multidiscip Healthc. .

Abstract

Purpose: The COVID-19 pandemic poses a serious threat to healthcare workers and hospitalized patients. Early detection of COVID-19 cases is essential to control the spread in healthcare facilities. However, real-world data on the screening criteria for hospitalized patients remain scarce. We aimed to explore whether patients with negative results of pre-hospital screening for COVID-19 should be rescreened after admission in a low-prevalence (less than 3% of the world average) setting.

Patients and methods: We retrospectively included patients in central Taiwan who were negative at the first screening but were newly diagnosed with pneumonia or had a body temperature above 38 degrees Celsius during their hospitalization. Each patient might be included as an eligible case several times, and the proportions of cases who were rescreened for COVID-19 and those diagnosed with COVID-19 were calculated. A logistic regression model was constructed to identify factors associated with rescreening. Reverse transcription-polymerase chain reaction tests were used to confirm the diagnosis of COVID-19.

Results: A total of 3549 cases eligible for COVID-19 rescreening were included. There were 242 cases (6.8%) who received rescreening. In the multivariable analysis, cases aged 75 years or older, those with potential exposure to SARS-CoV-2, or patients visiting specific departments, such as the Cardiovascular Center and Department of Neurology, were more likely to be rescreened. None was diagnosed with COVID-19 after rescreening. There was no known cluster infection outbreak in the hospital or in the local community during the study period and in the following two months.

Conclusion: In Taiwan, a country with a low COVID-19 prevalence, it was deemed safe to rescreen only high-risk hospitalized patients. This strategy was effective and reduced unnecessary costs.

Keywords: SARS-CoV-2; fever; pneumonia; risk; screen.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Similar articles

See all similar articles

Cited by

  • Differential diagnosis of COVID-19 and influenza.
    Alemi F, Vang J, Wojtusiak J, Guralnik E, Peterson R, Roess A, Jain P. Alemi F, et al. PLOS Glob Public Health. 2022 Jul 21;2(7):e0000221. doi: 10.1371/journal.pgph.0000221. eCollection 2022. PLOS Glob Public Health. 2022. PMID: 36962332 Free PMC article.
  • Prospective clinical surveillance for severe acute respiratory illness and COVID-19 vaccine effectiveness in Kenyan hospitals during the COVID-19 pandemic.
    Lucinde RK, Gathuri H, Isaaka L, Ogero M, Mumelo L, Kimego D, Mbevi G, Wanyama C, Otieno EO, Mwakio S, Saisi M, Isinde E, Oginga IN, Wachira A, Manuthu E, Kariuki H, Nyikuli J, Wekesa C, Otedo A, Bosire H, Okoth SB, Ongalo W, Mukabi D, Lusamba W, Muthui B, Adembesa I, Mithi C, Sood M, Ahmed N, Gituma B, Giabe M, Omondi C, Aman R, Amoth P, Kasera K, Were F, Nganga W, Berkley JA, Tsofa B, Mwangangi J, Bejon P, Barasa E, English M, Scott JAG, Akech S, Kagucia EW, Agweyu A, Etyang AO. Lucinde RK, et al. BMC Infect Dis. 2024 Nov 5;24(1):1246. doi: 10.1186/s12879-024-10140-6. BMC Infect Dis. 2024. PMID: 39501217 Free PMC article.

References

    1. World Health Organization. WHO Coronavirus (COVID-19) dashboard; 2021. Available from: https://covid19.who.int/. Accessed September 21, 2021.
    1. Zhou Q, Gao Y, Wang X, et al. Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis. Ann Trans Med. 2020;8(10):629. doi:10.21037/atm-20-3324 - DOI - PMC - PubMed
    1. Du Q, Zhang D, Hu W, et al. Nosocomial infection of COVID‑19: a new challenge for healthcare professionals. Int J Mol Med. 2021;47(4):1. doi:10.3892/ijmm.2021.4864. - DOI - PMC - PubMed
    1. Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020;288(3):335–344. doi:10.1111/joim.13089 - DOI - PMC - PubMed
    1. Li R, Tian J, Yang F, et al. Clinical characteristics of 225 patients with COVID-19 in a tertiary Hospital near Wuhan, China. J Clin Virol. 2020;127:104363. doi:10.1016/j.jcv.2020.104363 - DOI - PMC - PubMed